Get Social With Us

Levine of BioProcess Technology Consultants to Hold Book Signing at BIO

Date: April 30, 2010
Location: Acton, Massachusetts

Howard L. Levine, Ph.D., president and founder of BioProcess Technology Consultants, will hold a book signing at the 2010 BIO International Convention, May 3-6, in Chicago, Illinois.

Howard L. Levine, Ph.D., BioProcess Technology Consultants president and founder, will be signing the newly released report, The Development of Therapeutic Monoclonal Antibody Products, in the BIO Store from 1:00 PM – 2:30 PM on May 4 during the 2010 BIO International Convention, May 3-6, in Chicago, Illinois. The 334-page report is a comprehensive review and analysis of the Chemistry, Manufacturing, and Control (CMC) activities and regulatory requirements for the development of monoclonal antibody products from initial discovery through First-In-Human clinical trials. The report, authored by BioProcess Technology Consultants with critical input and review by GE Healthcare, also includes information on late-stage development and commercialization of these important biologic products and presents strategies for accelerating their development while minimizing risks and costs.

“Given the growing number of monoclonal antibody products in development, full knowledge and understanding of all aspects of development, manufacture, and quality control of these products is critical. This report offers essential strategic advice to senior executives and program managers on these critical issues and also provides a valuable technical and regulatory roadmap for the critical CMC activities required for the successful development of monoclonal antibody,” said Dr. Levine.

For more information or to order a copy of The Development of Monoclonal Therapeutic Antibody Products, go to, call 978-266-9114, or email The report is available in hard-copy format only for $1,595. Copies of the report will also be available for purchase at the BIO Store May 3-6, 2010.

About BioProcess Technology Consultants, Inc.

Founded in 1994, BioProcess Technology Consultants is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of new biopharmaceutical products. The company specializes in helping clients develop manufacturing processes and strategies and assists in developing product discovery and process development programs that help speed products from clone to commercial.® BioProcess Technology Consultants also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more about BioProcess Technology Consultants, visit